¡¾ÕªÒª¡¿ ÌØ·¢ÐÔѪС°å¼õÉÙÐÔ×Ïñ°£¨ITP£©ÊÇÒÔѪС°åÔÚÍø×´ÄÚÆ¤ÏµÍ³Öб»¾ÞÊÉϸ°û¹ý¶ÈÆÆ»µÎªÌØÕ÷µÄ×ÔÉíÃâÒßÐÔ¼²²¡¡£×î½üÑо¿·¢ÏÖ£¬ITPÓëT/Bϸ°ûÒì³£»î»¯µ¼ÖµÄÃâÒßʧÄÍÊÜÓйء£T/Bϸ°û³ä·Ö»î»¯ÐèÒª¹²´Ì¼¤Ðźţ¬¹²´Ì¼¤ÐźŲ»½öÄܵ÷½ÚT/Bϸ°û·´Ó¦£¬¶ÔÓÚÃâÒßϵͳµÄÆäËü·½ÃæÒàÓÐ×÷Óᣱ¾ÎĽ«¾Í¹²´Ì¼¤ÐźÅÔÚITP·¢²¡»úÖÆÖеÄ×÷Óü°ÆäÑо¿½øÕ¹×÷Ò»×ÛÊö¡£
¡¾¹Ø¼ü´Ê¡¿ ¹²´Ì¼¤Ðźţ»ÌØ·¢ÐÔѪС°å¼õÉÙÐÔ×Ïñ°£»×ÔÉíÃâÒß
¡¡¡¡Role of Costimulatory Signals in Idiopathic Thrombocytopenia Purpura ¡ª¡ª Review
¡¡¡¡AbstractIdiopathic thrombocytopenia purpura (ITP) is an autoimmune disease which is characterized by destruction of platelets by macrophages in the reticuloendothelial system. Recent studies suggest that ITP is related to the abnormal activation and apoptosis of T/B cells which lead to failure of immune tolerance.Now it is becoming clear that costimulatory signals are required for full T/B cell activation and assumed to modulate T/B cells responses as well as other aspects of the immune system. This review focuses on the role and state-of-the-art advancements of costimulatory signals in ITP.
¡¡¡¡Key wordscostimulatory signal; ITP; autoimmunity
¡¡¡¡ÌØ·¢ÐÔѪС°å¼õÉÙÐÔ×Ïñ°£¨idiopathic thrombocytopenia purpura, ITP£©ÊÇÒÔѪС°åÔÚµ¥ºË¾ÞÊÉϵͳ±»ÍÌÊÉϸ°ûÆÆ»µ¹ý¶àÒýÆðѪС°å¼õÉÙÎªÌØÕ÷µÄ×ÔÉíÃâÒßÐÔ¼²²¡¡£Ñо¿·¢ÏÖ£¬ÍâÖÜѪT¡¢BÁܰÍϸ°ûµÄ»î»¯¡¢ÔöÖ³¡¢µòÍöÒì³£ÓëITPµÄ·¢ÉúÃÜÇÐÏà¹Ø¡£T¡¢BÁܰÍϸ°û»î»¯ÔöÖ³ÐèҪ˫ÐźŴ̼¤£ºÏ¸°ûÊÜÌ壨TCR»òBCR£©Ó뿹ԽáºÏËùÌṩµÄ»î»¯ÆðʼÐźţ¬¼´µÚÒ»ÐźÅ,ϸ°û±íÃæ¸¨Öú·Ö×ÓÓëÏàÓ¦ÅäÌå½áºÏËùÌṩµÄÐͬ¹²´Ì¼¤Ðźţ¬¼´µÚ¶þÐźš£¹²´Ì¼¤ÐÅºÅÆô¶¯¡¢Î¬³Ö²¢µ÷½Ú»î»¯¼¶Áª·´Ó¦£¬ÎªÏ¸°û¿¹ÔÌØÒìÐÔ¼¤»îËù±ØÐè,Ëü¾ö¶¨ÁËϸ°ûÊǻÔöÖ³ÒÖ»òת±äΪÎÞÄÜ״̬(anergy)ÉõÖÁµòÍö(apoptosis)¡£½üÄêÀ´ÈËÃÇ¿ªÊ¼¹Ø×¢¹²´Ì¼¤ÐźŶÔITP·¢²¡ÓëÖÎÁƵÄÓ°Ï죬²ûÊÍITP»¼ÕßʧÄÍÊÜ»úÖÆºÍ̽Ë÷еÄÖÎÁƲßÂÔ¡£±¾ÎĽ«¾Í´Ë×÷Ò»×ÛÊö¡£¹²´Ì¼¤·Ö×Ó°´½á¹¹·ÖΪ£ºÃâÒßÇòµ°°×³¬¼Ò×壨B7¼Ò×壩ºÍTNF£¨tumor necrosis factor£©/TNFR(TNF receptor)³¬¼Ò×塣ĿǰΪֹ£¬ÓйØÓÚITPµÄ¹²´Ì¼¤ÐźÅÑо¿Éæ¼°µ½µÄÊÇ B7/CD28/CTLA-4ºÍCD40/CD40L¡£
¡¡¡¡ÃâÒßÇòµ°°×³¬¼Ò×å
¡¡¡¡B7-1/B7-2ÓëCD28/CTLA-4(cytotoxic T lymphocyte antigen-4)·Ö×Ó
¡¡¡¡CD28/ B7¡¢CTLA-4/B7ÊÇ×îÔç·¢ÏֵľµäµÄ¹²´Ì¼¤·Ö×Ó£¬ÔÚTϸ°ûµÄ»î»¯¹ý³ÌÖзֱðÌṩÕý¸ºµ÷½ÚÐźš£B7-1£¨CD80£©¡¢B7-2(CD86)»ùÒò·Ö±ð¶¨Î»ÓÚ3q13.3ºÍ3q21£¬Ö÷Òª±í´ïÓڻµÄBϸ°û¡¢Tϸ°û¡¢Ê÷ͻ״ϸ°û£¨DC£©¼°IFN-¦Ã»î»¯µÄµ¥ºËϸ°û¡£CD28ºÍCTLA-4»ùÒò¶¨Î»ÓÚ1q33£¬CD28·Ö×ӿɳÖÐø±í´ïÓÚCD4+¡¢CD8+Tϸ°û±íÃæ£¬¶øCTLA-4Ö»±í´ïÓÚ¼¤»îµÄCD4+¡¢CD8+Tϸ°û±íÃæ£¬ÇÒ±í´ïÁ¿Ö»ÓÐCD28µÄ2£¥-3£¥¡£B7-2×é³ÉÐͱí´ïÓÚ¿¹Ô³ÊµÝϸ°û£¨APC£©ÉÏ, δ¾´Ì¼¤µÄAPC²»±í´ï»òµÍ±í´ïB7-1£¬ÓÉ´ËÌáʾTϸ
¡¡¡¡°û¼¤»îµÄÔçÆÚ,Ö÷ÒªÓÉB7-2ÌṩTϸ°û»î»¯ËùÐèµÄ¹²´Ì¼¤ÐźÅ,¶øB7-1ÔòÔÚºóÐøµÄTϸ°û¿Ë¡ÔöÖ³ÖÐÆð×÷Óá£SuvasµÈ£Û1£ÝÑо¿·¢ÏÖ£¬B7-1¶ÔÆÕͨµÄBϸ°ûÔöÖ³ºÍIgG·ÖÃÚÌṩ¸ºµ÷½ÚÐźţ¬¶øB7-2ÔòÌṩÕýµ÷½ÚÐźš£CTLA-4ÓëCD28ÔڽṹÉÏÔ¼ÓÐ31%ÏàËÆ£¬µ«CTLA-4ÓëB7-1/2µÄÇ׺ÍÁ¦È´ÏÔÖø¸ßÓÚCD28ÇÒÉúÎïѧ×÷Óò»¾¡Ïàͬ¡£CD28ÓëB7·Ö×Ó½áºÏºó¿É´Ù½øTϸ°ûµÄ»î»¯¡¢·Ö»¯;CTLA-4ÔòÒÖÖÆTϸ°ûµÄÔöÖ³,´Ù½ø¿¹ÔÌØÒìÐÔÁܰÍϸ°ûµÄµòÍö,Ñо¿ÈÏΪÆä»úÖÆÎª: CTLA-4ÄÜÓëµ°°×ÀÒ°±ËáÁ×Ëáø(SHP2)Á¬½Ó£¬SHP2ÔÚTCR/CD3¸´ºÏÎïÉϵľۼ¯»áµ¼ÖÂÐźŸ´ºÏÎïµÄ·ÇÁ×Ëữ,²¢ÖÕÖ¹TCR½éµ¼µÄϸ°û»î»¯£Û2£Ý¡£
¡¡¡¡ÓëITPµÄÏà¹ØÑо¿
¡¡¡¡CuiµÈ£Û3£Ý¼ì²âµ½ÂýÐÔITP»¼Õß¹ÇËè¾ÞºËϸ°ûºÍÍâÖÜѪС°åB7-1±í´ïÉϵ÷£¬B7-1ˮƽÓ뻼Õß¾ÞºËϸ°ûÊýÖµºÍ×ÔÉí¿¹ÌåPAIgGˮƽ³ÊÕýÏà¹Ø£»ÔÚÌåÍâʵÑéÖиøÓèB7-1µ¥¿Ë¡¿¹ÌåÄÜ´Ù½ø¾ÞºËϸ°ûÊýÔöÖ³¡£ÔøÑ޵ȣÛ4£Ý¼ì²âÁËITP»¼ÕßÍâÖÜѪÀ´Ô´Ê÷ͻ״ϸ°û£¨DC£©±íÃæB7-1¡¢B7-2µÄ±í´ïˮƽ£¬½á¹ûÏÔʾITP»¼ÕßÍâÖÜѪDC±í´ïB7-1¡¢B7-2Éϵ÷£¬ÍƲâITP»¼Õßͨ¹ýÐͬ´Ì¼¤·Ö×ӵIJîÒì±í´ï,ÔöÇ¿DC¿¹Ô³ÊµÝ¹¦ÄÜ,ʹµÃ×ÔÉí·´Ó¦ÐÔϸ°û¹ý¶È»î»¯,µ¼Ö»¼Õß¶Ô×ÔÉíѪС°åÃâÒßʧÄÍÊÜ¡£¸ßÇ寽µÈ£Û5£Ý±¨µÀ£¬ITP»¼ÕßÍâÖÜѪBϸ°û±íÃæB7-1ºÍB7-2±í´ïÃ÷ÏÔÉÏÉý¡£×ÛÉÏËùÊö£¬ITP»¼ÕßB7-1ºÍB7-2µÄÒì³£±í´ï¿ÉÄÜÓ뻼ÕßÌåÄÚÃâÒßϸ°ûµÄ¸ß×ÔÉí·´Ó¦ÐÔÒÔ¼°Òì³£µÄ¹²´Ì¼¤ÐźŲúÉúÓйء£NagafuchiµÈ£Û6£Ý¼ì²âµ½ÏµÍ³ÐÔºì°ßÀÇ´¯»¼ÕßBϸ°ûB7-1¡¢B7-2¹ý¶È±í´ï, ÀûÓÿ¹B7-2µ¥¿Ë¡¿¹ÌåÖÎÁÆÏµÍ³ÐÔºì°ßÀÇ´¯¿ÉÒÖÖÆ¿¹dsDNA ¿¹Ìå²úÉú¡£µ«¶ÔÓÚͬÑùÊÇ×ÔÉíÃâÒß²¡µÄITPÀ´Ëµ£¬¿¹B7-2µ¥¿Ë¡¿¹ÌåÄÜ·ñ¸ÉÔ¤ITP×ÔÉíÃâÒß·´Ó¦,ÒÖÖÆ×ÔÉí¿¹Ìå²úÉú,ÉдýÑо¿¡£Ï¸°û¶¾ÐÔTÁܰÍϸ°ûÏà¹Ø¿¹Ô4ÃâÒßÇòµ°°×(cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin,CTLA-4 Ig)Êǽ«±í´ïÔڻTϸ°ûÉϵÄÈËCTLA-4·Ö×ӵİûÍ⹦ÄÜÇøÓëIgG1µÄºã¶¨ÇøÔÚ»ùÒòˮƽÉÏÏà½áºÏµÄÈںϵ°°×,ÓëB7ÓиßÇ׺ÍÁ¦£¬ÊÇÓÕµ¼ÌØÒìÐÔÃâÒßÄÍÊܵÄ×îÓÐÐ§ÖÆ¼Á¡£PengµÈ£Û7£ÝÌåÍâʵÑé֤ʵ£¬µ¥¶ÀʹÓÃCTLA-4 Ig»òÁªºÏ»·æß¾úËØ£¨CsA£©¿ÉÒÔ×è¶ÏTÁܰÍϸ°ûB7/CTLA-4¹²´Ì¼¤Í¨Â·£¬ÓÕµ¼²úÉúѪС°åÌØÒìÐÔÎÞÄÜTϸ°û£¬´Ó¶øÃ÷ÏÔÒÖÖÆÑªÐ¡°åÆÆ»µÇÒ¶¾¸±×÷ÓÃС£¬ÏÔʾÁËDZÔÚµÄÓ¦ÓüÛÖµ¡£
TNF/TNFR¼Ò×å
¡¡¡¡CD40/CD40L(CD154)
¡¡¡¡CD40Ö÷Òª±í´ïÔÚBϸ°û¡¢ÐØÏÙÉÏÆ¤Ï¸°û¡¢»î»¯µÄµ¥ºË/¾ÞÊÉϸ°û¡¢Ê÷ͻ״ϸ°û¡¢ÄÚÆ¤Ï¸°û¼°Ò»Ð©Ö×Áöϸ°û¡£ÈËCD40LµÄ»ùÒò¶¨Î»ÓÚXq2613¡ª2711£¬Ö÷Òª±í´ïÓڻCD4+Tϸ°ûÒÔ¼°²¿·ÖCD8£«T ϸ°û¡£ÔÚÌåÄÚÓпÉÈÜÐÔCD40L (sCD40L)ÄÜÓëϸ°û±íÃæCD40×÷Óá£CD40/CD40LÔÚ¿¹ÌåµÄÐγÉÖÐÆðÖØÒª×÷Ó㺠CD4£«Tϸ°û±íÃæµÄCD40LÓëδÖÂÃôµÄBϸ°û±íÃæµÄCD40·Ö×Ó½áºÏºó£¬Ê¹Bϸ°û·¢ÉúÔöÖ³¡¢Àà±ðת»»¡¢·Ö»¯³É½¬Ï¸°û£¬ÒÖÖÆBϸ°ûµòÍö£¬Éϵ÷»î»¯Tϸ°ûºÍDC±íÃæCD80ºÍCD86µÄ±í´ï£¬ÓÕµ¼DCºÍ¾ÞÊÉϸ°û·ÖÃÚÑ×ÐÔÒò×Ó£¬ÓÕµ¼DC±í´ï¸ü¶àµÄMHC·Ö×Ó¡£
¡¡¡¡ÓëITPµÄÏà¹ØÑо¿
¡¡¡¡×è¶ÏCD40LÄÜÒÖÖÆCTL»î»¯£¬ÌáʾÔÚCD4+ϸ°ûÒÀÀµµÄCTL»î»¯ÖÐCD40/CD40LÒ²ÆðÖØÒª×÷Óá£Í¨³£ÑªÐ¡°åÄÚºÍĤ±íÃæµÍ±í´ïCD154£¬µ±ÑªÐ¡°å»î»¯ºóÆä±í´ïÔö¼Ó£Û8£Ý£¬Õâ¶ÔÓÚITPµÄ·¢²¡ÓÐÖØÒªÒâÒ塣ѪС°å±íÃæµÄCD154ÓëѪС°åÉϵÄÖîÈçGPIIb/IIIaµÈ¿¹ÔÒ»ÆðΪBϸ°û»î»¯Ìṩ¹²´Ì¼¤Ðźţ¬²¢ÇÒѪС°åÔ´CD154ÄÜ´Ù½øÊ÷ͻ״ϸ°ûÏò³ÉÊì·Ö»¯£¬Éϵ÷Ê÷ͻ״ϸ°û¹²´Ì¼¤·Ö×ӵıí´ï£Û9£Ý¡£SolanillaµÈ£Û10£Ý±¨µÀ£¬ÔÚITP»¼ÕßÌåÄÚѪС°åÏà¹ØÐÔCD154±í´ïÉý¸ß£¬²¢ÇÒµ¼Ö»¼Õß×ÔÉí·´Ó¦ÐÔBÁܰÍϸ°ûÒì³£»î»¯¡£NagahamaµÈ£Û11£Ý·¢ÏÖ£¬65ÀýITP»¼ÕßÖÐÓÐ38Àý(58.5%)Ѫ½¬¿ÉÈÜÐÔCD40L£¨sCD40L£©Ë®Æ½Éý¸ß,ÇÒÖÎÁÆÕßÏÔÖø¸ßÓÚδÖÎÁÆÕß¡£CD40LÑôÐÔ»¼ÕßµÄѪС°åÊýÃ÷ÏÔϽµ£¬¶ÔÓÚ²¿·ÖsCD40LÉý¸ßµÄ»¼ÕßCD40/CD40L¿ÉÄܲÎÓëITPµÄ·¢²¡¡£È»¶øFan µÈ£Û12£ÝµÄʵÑé½á¹ûÔòºÍNagahama²»¾¡Ïàͬ£¬ËûÃǵÄÑо¿½á¹ûÏÔʾITP»¼ÕßѪ½¬sCD40LˮƽºÍÕý³£¶ÔÕÕÕßûÓÐÃ÷ÏÔ²î±ð£¬µ«ÊÇѪÇåsCD40LˮƽȴÏÔÖøµÍÓÚÕý³£¶ÔÕÕÕß¡£Õâ¿ÉÄÜÊÇÒòΪ»î»¯µÄѪС°å±í´ïsCD40L£¬µ±»î»¯µÄѪС°åÔÚµ¥ºËÍÌÊÉϵͳ±»ÆÆ»µºósCD40LÊÍ·ÅÈëѪ¡£ÓÉ´ËÍÆ²âCD40/CD40L¹²´Ì¼¤Í¨Â·µÄÒì³£²ÎÓëÁËITPµÄ·¢²¡£¬µ«ÆäÖ²¡µÄ¾ßÌå»úÖÆÈÔÓдýÑо¿¡£ BusselµÈ£Û13£Ý±¨µÀÓÿ¹CD154µ¥¿Ë¡¿¹Ì壨antova£©¶Ô19ÀýÄÑÖÎÐÔITP»¼Õß½øÐÐÖÎÁÆ,¼ÁÁ¿Îª10-20 mg/kg¾²Âö×¢Éä,¼ä¸ô2-4ÖÜ1´Î,ÆäÖÐ10Àý³öÏÖѪС°åÉý¸ß¡£